Protocol Ledger

NCT07450599 · Phase II · RECRUITING

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

Interventional Phase II clinical trial protocol NCT07450599 sponsored by Bayer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-27 Enrollment: 250 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07450599
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)250 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07450599
Protocol FieldVerified Registry Value
NCT IdentifierNCT07450599
Consolidated Lead SponsorBayer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment250 participants (ESTIMATED)
Registered Start Date2026-04-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI